Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

[Indirect comparison of different adjuvant chemotherapies for stage II-III gastric cancer after D2 gastrectomy in Asian patients].

Jiang ZM, Wei Y, Zhang YD, Zhou SW, Yang Q, Xie DR.

Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Jun;16(6):534-7. Chinese.

PMID:
23801205
2.

Economic evaluation of first-line adjuvant chemotherapies for resectable gastric cancer patients in China.

Tan C, Peng L, Zeng X, Li J, Wan X, Chen G, Yi L, Luo X, Zhao Z.

PLoS One. 2013 Dec 10;8(12):e83396. doi: 10.1371/journal.pone.0083396. eCollection 2013.

3.

Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.

Wu B, Li T, Cai J, Xu Y, Zhao G.

BMC Cancer. 2014 Dec 19;14:984. doi: 10.1186/1471-2407-14-984.

4.

Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East.

Fujitani K.

Dig Surg. 2013;30(2):119-29. doi: 10.1159/000350877. Epub 2013 Jul 18. Review.

PMID:
23867588
5.

Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric Cancer.

Chongqing T, Liubao P, Xiaohui Z, Jianhe L, Xiaomin W, Gannong C, Siying W, Lihui O, Ziying Z.

Pharmacoeconomics. 2014 Mar;32(3):235-43. doi: 10.1007/s40273-013-0065-2.

PMID:
23709451
6.

[Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): Chinese subgroup analysis].

Ji J, Liang H, Zhan Y, Liu Y, He Y, Ye Y, Sun Y, Huang C, Yan M, Shi Y, Wu A.

Zhonghua Wei Chang Wai Ke Za Zhi. 2014 Feb;17(2):133-8. Chinese.

PMID:
24577767
7.

Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer.

Wu Y, Wei ZW, He YL, Schwarz RE, Smith DD, Xia GK, Zhang CH.

World J Gastroenterol. 2013 Jun 7;19(21):3309-15. doi: 10.3748/wjg.v19.i21.3309.

8.

[Meta-analysis of adjuvant chemotherapy on prognosis for gastric cancer patients after D2 dissection].

Xia GG, Zhang CH, Wei ZW, Wu Y, He YL.

Zhonghua Wai Ke Za Zhi. 2013 May 1;51(5):447-51. Chinese.

PMID:
23958170
9.

Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.

Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y.

J Clin Oncol. 2011 Nov 20;29(33):4387-93. doi: 10.1200/JCO.2011.36.5908. Epub 2011 Oct 17.

10.

Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.

Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenbarg EM, Boot H, Putter H, Peeters KC, van de Velde CJ, Verheij M.

J Clin Oncol. 2010 May 10;28(14):2430-6. doi: 10.1200/JCO.2009.26.9654. Epub 2010 Apr 5.

11.

Adjuvant chemotherapy for elderly patients with gastric cancer after D2 gastrectomy.

Jin Y, Qiu MZ, Wang DS, Zhang DS, Ren C, Bai L, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH.

PLoS One. 2013;8(1):e53149. doi: 10.1371/journal.pone.0053149. Epub 2013 Jan 24.

12.

Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.

Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S; Gastric Cancer Surgical Study Group, Japan Clinical Oncology Group.

J Clin Oncol. 2003 Jun 15;21(12):2282-7.

PMID:
12805327
13.

Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer.

Sun P, Xiang JB, Chen ZY.

Br J Surg. 2009 Jan;96(1):26-33. doi: 10.1002/bjs.6408. Review.

PMID:
19016271
14.

Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis.

GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M.

JAMA. 2010 May 5;303(17):1729-37. doi: 10.1001/jama.2010.534. Review.

PMID:
20442389
15.

Adjuvant and neoadjuvant therapy for gastric cancer.

Kelsen DP.

Semin Oncol. 1996 Jun;23(3):379-89. Review.

PMID:
8658222
16.

Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 Lymphadenectomy: a meta-analysis.

Huang YY, Yang Q, Zhou SW, Wei Y, Chen YX, Xie DR, Zhang B.

PLoS One. 2013 Jul 18;8(7):e68939. doi: 10.1371/journal.pone.0068939. Print 2013. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/e783be87-404d-4780-9159-bfd1ade5c3a4.

17.

A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer.

Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, Morris DL.

Ann Surg Oncol. 2007 Oct;14(10):2702-13. Epub 2007 Jul 26. Review.

PMID:
17653801
18.

[Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].

Diao C, Cheng RC, Zhang JM, Wei XP, Su YJ, Liu QY, Xu JB.

Zhonghua Zhong Liu Za Zhi. 2008 Feb;30(2):147-50. Chinese.

PMID:
18646702
19.

Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy.

Tamura S, Fujitani K, Kimura Y, Tsuji T, Matsuyama J, Iijima S, Imamura H, Inoue K, Kobayashi K, Kurokawa Y, Furukawa H; Osaka Gastrointestinal Cancer Chemotherapy Study Group.

Oncology. 2011;80(5-6):296-300. doi: 10.1159/000329090. Epub 2011 Jul 18.

PMID:
21778769
20.

[Effectiveness of precautionary chemotherapy in gastric cancer].

Rimassa L, Campagnoli E, Biancofiore G.

Tumori. 2000 Sep-Oct;86(5 Suppl 2):S5-13. Review. Italian.

PMID:
11195303
Items per page

Supplemental Content

Write to the Help Desk